Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.62 |
| ▸ | CTSC | P53634 | 8/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10441228 | 0.93 | MMP2 (0.55) | MMP2CTSCLTA4HCYP1A2CYP3A4 | |
| SCHEMBL10633263 | 0.90 | CTSC (0.60) | MMP2CTSCLTA4HERAP2LNPEP | |
| SCHEMBL9132107 | 0.90 | CTSC (0.60) | MMP2CTSCLTA4HERAP2LNPEP | |
| SCHEMBL2196618 | 0.90 | CTSC (0.60) | MMP2CTSCLTA4HERAP2LNPEP | |
| SCHEMBL11133028 | 0.90 | CTSC (0.60) | MMP2CTSCLTA4HERAP2LNPEP | |
| SCHEMBL9132111 | 0.90 | CTSC (0.60) | MMP2CTSCLTA4HERAP2LNPEP | |
| SCHEMBL4672649 | 0.89 | MMP2 (0.48) | MMP2CTSCERAP2LNPEP | |
| SCHEMBL4672644 | 0.89 | MMP2 (0.48) | MMP2CTSCERAP2LNPEP | |
| SCHEMBL9828439 | 0.88 | CTSC (0.57) | MMP2CTSCCYP1A2CYP3A4CTSH | |
| SCHEMBL15754331 | 0.87 | MMP2 (0.57) | MMP2CTSCLTA4HERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, CTRC | MMP2 2781/4885CTSC 192/4885LTA4H 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.